Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call

West Pharmaceutical Servs (NYSE: WST ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

APIs provide real-time access to earnings call transcripts and financial data.

Visit to learn more.

The full earnings call is available at Summary West Pharmaceutical Services reported strong Q2 2026 results, with revenues of $872 million up 13% organically and adjusted EPS of $2.37 up 29% from the prior year.

The company raised its full-year 2026 guidance, expecting organic revenue growth of 10% to 11% and adjusted EPS between $8.85 and $9.05.

Key growth drivers included the Proprietary Products segment with 16% organic growth, particularly in the biologics market which saw 29% growth, and HVP components accounting for 49% of total revenues.

West Pharmaceutical Services emphasized the strength and expansion of its GLP-1 components and Annex 1-related projects as significant contributors to growth.

Operational excellence initiatives and recovery from a cyber incident were highlighted as contributors to performance, alongside strategic expansions in Asia Pacific and partnerships like the renewed agreement with Daikyo.

Management reiterated confidence in long-term growth prospects driven by biologics, biosimilars, and GLP-1 therapies, with ongoing efforts to improve margins and operational efficiency.

Full Transcript OPERATOR Good day and welcome to the West Pharmaceutical Servs Q2 2026 earnings conference call.

At this time, all participants are in a listen-only mode.

After the speaker presentation, there will be a question-and-answer session.

To ask a question during that session, you will need to press star 11 on your telephone.

You will then hear an automated message advising your hand is raised.

To withdraw your question, please press star 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker, Mr.

John Sweeney, Vice President of Investor Relations.

Please go ahead, sir.

John Sweeney, Vice President of Investor Relations Good morning and welcome to West's second quarter 2026 earnings conference call, which is being webcast live today.

Today with me on the call are Eric Green, our CEO, Chair of the Board, and Bob McMahon, CFO.

Earlier today, we issued our second quarter financial results.

A copy of the press release, along with today's slide presentation containing supplemental information for your reference, has been posted in the Investors section of the company's website at investor.westpharma.com.

Later today, a replay of the webcast will also be available in the Investors section of our website.

Before we begin, we'd like to remind you that statements made by management during this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities laws.

Please refer to the accompanying safe harbor statement currently being displayed on the screen and in today's press release, in addition to other disclosures made by the company such as our 10-K and 10-Q, regarding the risks to which the company is subject.

During the call, management will also report on certain non-GAAP financial measures, including organic net sales, adjusted operating profit, adjusted operating profit margin, free cash flow, and adjusted diluted earnings per share.

The accompanying disclosure statement, as well as reconciliations of these non-GAAP financial measures to the most comparable financial results prepared in conformity with U.S.

GAAP, are provided in this morning's press release and today's presentation materials.

I'll now turn the call over to our CEO, Eric Green.

Eric Green, CEO & Chair of the Board Thank you, John, and good morning, everyone.

Thanks for joining us today.

I am pleased to report strong second quarter results which exceeded our expectations on the top and bottom line.

Revenues of $872 million were up 13% organically, and adjusted EPS of $2.37 was up 29% as compared to prior year.

Our performance was driven by the execution of our strategy and continued operational excellence initiatives.